Evidence map›Paper›PMID 34756674›Full record

ArticleJournal of clinical lipidology

Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis.

Karan Mathur, Eduardo Vilar-Gomez, Margery A Connelly, Hanchang He, Arun J Sanyal, Naga Chalasani, Z Gordon Jiang

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Lipid Droplet Dynamics in Alcoholic Steatohepatitis.The American journal of pathology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Karan MathurDivision of Gastroenterology & Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Eduardo Vilar-GomezDivision of Gastroenterology & Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Margery A ConnellyLaboratory Corporation of America Holdings (Labcorp), Morrisville, NC, USA.
Hanchang HeDivison of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Arun J SanyalDivision of Gastroenterology and Hepatology, Virginia Commonwealth University, Richmond, Virginia.
Naga ChalasaniDivision of Gastroenterology & Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Z Gordon JiangDivison of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: zgjiang@bidmc.harvard.edu.
Indiana University School of MedicineBeth Israel Deaconess Medical Center · USLabCorp (United States) · USVirginia Commonwealth University · US

Funding

Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-IU)U01AA021840 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI NAGA P CHALASANI, Olawale Ojo · 2012 to 2026
$8.1M
TREAT-MayoU01AA021788 · NIAAA · MAYO CLINIC ROCHESTER · PI MALHI, HARMEET, SHAH, VIJAY H. · 2012 to 2022
$4.7M
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) - Virginia Commonwealth UniversityU01AA026979 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Juan Pablo Arab Verdugo, FREDERICK Gerard MOELLER · 2018 to 2026
$2.9M
TREAT-VCUU01AA021891 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI SANYAL, ARUN J · 2012 to 2017
$2.5M
Adenosine deaminase 2 regulates macrophage phenotype and liver fibrosis in nonalcoholic fatty liver diseaseK08DK115883 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI JIANG, ZHENGHUI GORDON · 2018 to 2022
$839k
Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-ADMIN)U01AA021883 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI CRABB, DAVID W · 2012 to 2017
$229k
NCATS NIH HHS UL1 TR002649NIAAA NIH HHS U01 AA021788NIAAA NIH HHS U01 AA021840NIAAA NIH HHS U01 AA021883NIAAA NIH HHS U01 AA021891NIAAA NIH HHS U01 AA026979NIDDK NIH HHS K08 DK115883NIDDK NIH HHS L30 DK118655
6 · The paper itself

Abstract

backgroundAlcohol-associated liver disease (ALD) and alcoholic hepatitis (AH) significantly impact the liver, an organ central to the lipid and lipoprotein metabolism.

objectiveTo define changes in the lipid and lipoprotein profiles in subjects with alcoholic hepatitis (AH) versus heavy drinkers with normal liver function and to determine the association of the AH-mediated lipoprotein phenotype with AH severity and outcomes.

methodsAH cases (n=196) and a heavy drinker control group (n=169) were identified in a multicenter, prospective cohort. The relationships between lipid panels and lipoprotein profiles among AH and heavy drinkers were interrogated using three common measurements: the conventional lipid panel, extended lipid panel by NMR, and NMR-based direct lipoprotein profiling. Predictive values for AH severity and mortality were determined using Harrell's C-Index.

resultsLipid and lipoprotein profiles were significantly different in AH compared to heavy drinkers. Among them, high density lipoprotein (HDL) particle concentration exhibited the most significant reduction in AH compared to heavy drinkers (5.3 ± 3.4 vs 22.3 ± 5.4 μmol/L, p < 0.001). Within AH patients, HDL particle concentration was inversely associated with Maddrey's Discriminant Function (DF) (p < 0.001), and independently associated with mortality at both 90 and 365 days even after adjustment for DF (p = 0.02, p = 0.05 respectively). HDL particle concentration less than 3.5 μmol/L and total cholesterol ≤ 96 mg/dL identified AH patients with higher 90-day mortality.

conclusionLipid and lipoprotein profiles are profoundly altered in AH and can help in prognosticating disease severity and mortality.

Indexed as

AdultAlcoholismCholesterolDiagnosis, DifferentialFemaleHepatitis, AlcoholicHumansKaplan-Meier EstimateLipidsLipoproteinsLipoproteins, HDLMagnetic Resonance SpectroscopyMaleMiddle AgedPrognosisProspective StudiesCholesterolLipidsLipoproteinsLipoproteins, HDLAlcoholic hepatitis (AH)high density lipoprotein (HDL)lipoproteinsNuclear magnetic resonance spectroscopy (NMR)total cholesterol (TC)

Identifiers

PMID34756674
PMCPMC8688310
OpenAlexW3205623298

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.